Skip to main content

Table 1 Characteristics of included studies

From: Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials

Author (year)

Country

Age*

Sample size

Dosage

Follow-up period (weeks)

 
   

Glimepiride

Metformin

Glimepiride

Metformin

Ref

Ling (2003)

China

Female 54 (8.3)

50

44

1-6 mg/day

750-1750 mg/day

12

[33]

  

Male 53 (9.2)

      

Ramachandran (2004)

India

30-60

18

21

1-2 mg/day

250-850 mg/day

14

[34]

Derosa (2004)

Italian

46-67

81

83

2-4 mg/day

2000-3000 mg/day

52

[35]

Gonzolez (2004)

Mexico

40-65

37

33

2 mg/day

2000 mg/day

12

[36]

Rong (2004)

China

42 (11)

98

100

4 mg/day

1500 mg/day

12

[22]

Tang (2004)

China

35-70

33

29

1-2 mg/day

750-1500 mg/day

26

[37]

Yamanouchi (2005)

Japan

Metformin 54.7 (9.8)

37

39

1-2 mg/day

750 mg/day

52

[20]

  

Glimepiride 53 (9.2)

      

Ning (2006)

China

35-70

51

50

1-6 mg/day

250 mg bid-750 mg tid

52

[38]

Wu (2007)

China

30-70

40

30

1-6 mg/day

250-2000 mg tid

12

[39]

Xu (2007)

China

35-70

34

34

1-6 mg/day

250 mg to maximum bid

-

[40]

Li (2007)

China

32-70

35

33

2-6 mg/day

250-1500 mg bid

65

[41]

Wang (2009)

China

45 (7)

49

50

4-6 mg/day

1500 mg/day

12

[23]

Rahman (2011)

Pakistan

Metformin 51.9 (14.1)

102

102

2-8 mg/day

500-2000 mg/day

52

[42]

  

Glimepiride 52 (15.4)

      

Yoon (2011)

Korea

30-65

118

114

2 mg/day

500 mg/day

48

[21]

Wang (2011)

China

33-70

68

68

2 mg/day

500 mg bid

12

[43]

  1. * presented in range or mean (standard deviation).